Cagrilintide
Phase 3aka AM833
Long-acting amylin analog, usually run alongside semaglutide as CagriSema.
Mechanism
An amylin receptor agonist that drives satiety and slows gastric emptying, a different lever than GLP-1. Stack it with semaglutide (that combo is CagriSema) and the two mechanisms add up.
Regulatory & Safety Status
Investigational (Novo Nordisk), late-stage trials. Not approved yet.
Research
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
Latest cagrilintide research